

# Contents

<b>1</b>	<b>Letter from the Editor</b>	<b>6</b>
<b>2</b>	<b>Did Twitter Mood Really Predict the DJIA? Misadventures in Big Data for Finance</b>	<b>8</b>
2.1	Introduction . . . . .	10
2.1.1	Review of TMP and Outline . . . . .	10
2.2	Implied Sharpe Ratio Exceeds That of Any Previously Discovered Strategy . . . . .	11
2.3	Multiple Comparison Bias . . . . .	14
2.3.1	Controlling the Familywise Error Rate . . . . .	20
2.3.2	Controlling False Discovery Rate . . . . .	27
2.3.3	Multiple Hypothesis Testing for Non-linear Machine Learning Algorithms . . . . .	30
2.3.4	Conclusions . . . . .	32
2.4	A Second Potential Error . . . . .	33
2.4.1	Monte Carlo Simulation 1: Fatal Inference . . . . .	34
2.4.2	Monte Carlo Simulation 2: Hedonic Treadmill . . . . .	39
2.5	Lots of Computation but Not Much Science: Future Work . . . . .	42
<b>3</b>	<b>Applications of Machine Learning in Forecasting Regressions: Boosting United States and Japan</b>	<b>49</b>
3.1	Introduction . . . . .	51
3.2	Related Work . . . . .	53
3.2.1	Predicting U.S's Recessions . . . . .	53

3.2.2	Predicting Japan’s Recessions . . . . .	55
3.2.3	Forecasting Recession Methods . . . . .	55
3.3	Methodology . . . . .	58
3.3.1	Logit . . . . .	58
3.3.2	Boosting . . . . .	58
3.4	Data and Evaluation . . . . .	66
3.4.1	United States . . . . .	66
3.4.2	Japan . . . . .	67
3.4.3	Evaluation Criteria . . . . .	71
3.5	Forecast Results in United States . . . . .	72
3.5.1	In-Sample Results . . . . .	73
3.5.2	Out-Of-Sample Results . . . . .	75
3.6	Forecast Results in Japan . . . . .	80
3.6.1	In-Sample Results . . . . .	81
3.6.2	Out-Of-Sample Results . . . . .	83
3.7	Conclusion . . . . .	88
<b>4</b>	<b>Sifting Through the Trans-Pacific Partnership: Contention, Compromise, and Potential Implications</b>	<b>94</b>
4.1	Introduction . . . . .	96
4.2	Safeguards Against Currency Manipulation . . . . .	98
4.3	Investor-State Dispute Settlement . . . . .	102
4.4	Trade Adjustment Assistance . . . . .	106
4.5	Intersections Between Currency Manipulation and Dispute Settlement . . . . .	107
<b>5</b>	<b>Pharmaceutical Copay Assistance Programs and Patient Drug Choice: Biological Specialty Drugs</b>	<b>117</b>
5.1	Introduction . . . . .	119

5.2	Background . . . . .	123
5.3	Related Literature . . . . .	126
5.3.1	Multi-tiered copay schemes . . . . .	126
5.3.2	Pharmaceutical pricing strategy . . . . .	128
5.3.3	Contribution . . . . .	129
5.4	Data . . . . .	130
5.4.1	Description of Sample Construction and Variables of Interest . . . . .	130
5.4.2	Summary Statistics . . . . .	135
5.5	Empirical Methodology . . . . .	142
5.6	Results . . . . .	145
5.6.1	Comparing brands that did not introduce coupons to those that did . . . . .	145
5.6.2	Assessing the impact of coupons on copay bands . . . . .	148
5.6.3	Do coupons change the share of the cost covered by insurance? . . . . .	150
5.7	Conclusion . . . . .	153